<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641783</url>
  </required_header>
  <id_info>
    <org_study_id>YL2012-03</org_study_id>
    <nct_id>NCT01641783</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients</brief_title>
  <official_title>To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanqiao Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer remains one of the major causes of cancer deaths around the world,especially&#xD;
      in Asia. For advanced gastric cancer,even if treated with chemotherapy,the prognosis is still&#xD;
      poor, so the investigators urgently need an effective strategy to treat advanced gastric&#xD;
      cancer, however, there was no recommended First-line chemotherapy for advanced gastric&#xD;
      cancer. Taxane is promising in gastric cancer. Nanoparticle Albumin-Bound (Nab) Paclitaxel&#xD;
      (Abraxane，ABI-007) with high effectiveness and low toxicity had been approved in breast&#xD;
      cancer as first-line chemotherapy in many countries. The investigator then initiated a&#xD;
      prospective phase II clinical trial with Nab-Paclitaxel plus Capecitabine as the first-line&#xD;
      treatment in advanced gastric cancer to observe the efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single arm,open,phase II study of Nab-Paclitaxel plus Capecitabine as the first-line&#xD;
      treatment in advanced gastric cancer.&#xD;
&#xD;
      Nab-Paclitaxel should be given intravenously on days 1 and 8 at a dose as follows. Treatment&#xD;
      should be repeated every 3 weeks:Nab-Paclitaxel:125 mg/m2; Capecitabine should be given&#xD;
      orally twice a day as follows for 14 consecutive days, followed by a 1-week rest. Treatment&#xD;
      should be repeated every 3 weeks. Capecitabine:1000mg/m2,twice daily (bid).&#xD;
&#xD;
      If applicable,the value of response and prognosis predictive factors are expected to be&#xD;
      identified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>the follow-up visit of PFS will be performed every 6 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>CT/MRI/Ultrasound will be performed every 2 cycles of treatment for efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival of participants</measure>
    <time_frame>2 years</time_frame>
    <description>OS means that from the first dose of treatment drug to death or lost,the follow-up visit will be performed every 3 months till death or lost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarkers</measure>
    <time_frame>6 weeks</time_frame>
    <description>To identify the molecular biomarkers(such as SPARK,β-Tubulin III,caveolin,etc)by immunohistochemical and western-bloting before and during therapy,to study the biomarkers correlations with clinical outcome and toxicity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>nanoparticle Albumin-bound paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evaluate one dose level of nab-paclitaxel:125mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanoparticle Albumin-Bound paclitaxel</intervention_name>
    <description>nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv</description>
    <arm_group_label>nanoparticle Albumin-bound paclitaxel</arm_group_label>
    <other_name>ABI-007</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent form;&#xD;
&#xD;
          -  histologically or cytologically confirmed gastric cancer;&#xD;
&#xD;
          -  Age 18-75 years;&#xD;
&#xD;
          -  Advanced or recurrent, metastatic disease;&#xD;
&#xD;
          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks;&#xD;
&#xD;
          -  At least have one measurable disease(according to RECIST, Response Evaluation Criteria&#xD;
             in Solid Tumors );&#xD;
&#xD;
          -  no prior history of chemotherapy or beyond 6 months after the end of systemic adjuvant&#xD;
             treatment;&#xD;
&#xD;
          -  Haematopoietic status:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1.5 x 109/L;&#xD;
&#xD;
               -  Platelet count &gt; 90 x 109/L;&#xD;
&#xD;
               -  Hemoglobin at least 90g/l;&#xD;
&#xD;
          -  Hepatic status:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal (ULN);&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times ULN(no liver metastasis), ≤ 5 times ULN (with liver&#xD;
                  metastasis);&#xD;
&#xD;
               -  ALP ≤ 2.5 times ULN(no liver metastasis), ≤5 times ULN(with liver or bone&#xD;
                  metastasis);&#xD;
&#xD;
               -  serum albumin ≥ 30g/L;&#xD;
&#xD;
          -  Renal status:&#xD;
&#xD;
               -  Creatinine ≤ 1.5 times ULN or calculated creatinine clearance, using the&#xD;
                  Cockcroft-Gault formula, ≥ 40 mL/min;&#xD;
&#xD;
          -  Able to swallow and retain oral medication;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  peripheral neuropathy of grade 2 or greater;&#xD;
&#xD;
          -  symptomatic brain metastasis;&#xD;
&#xD;
          -  known history of uncontrolled or symptomatic angina;&#xD;
&#xD;
          -  clinically significant arrhythmias, congestive heart failure, uncontrolled&#xD;
             hypertension (≥ 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic&#xD;
             therapy with oxygen;&#xD;
&#xD;
          -  dementia, altered mental status, or any psychiatric condition that would prevent the&#xD;
             understanding or rendering of ICF;&#xD;
&#xD;
          -  active or uncontrolled infection;&#xD;
&#xD;
          -  pregnant or lactating women;&#xD;
&#xD;
          -  dysmetabolism with nanoparticle Albumin-bound paclitaxel or Capecitabine&#xD;
&#xD;
          -  unable to swallow and retain oral medication,intestinal Obstruction,alimentary tract&#xD;
             hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqiao Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanqiao Zhang, M.D.</last_name>
    <phone>86-0451-86298222</phone>
    <email>yanqiaozhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming yang, Master</last_name>
    <phone>86-0451-86298281</phone>
    <email>yangming_0517@163.com</email>
  </overall_contact_backup>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Third Affiliated Hospital of Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yanqiao Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>advanced</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>capecitabine</keyword>
  <keyword>first line therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

